A Study Collecting Blood Samples From Pregnant Women to Aid in the Development of a Noninvasive Prenatal Test
Status: | Active, not recruiting |
---|---|
Conditions: | Women's Studies |
Therapuetic Areas: | Reproductive |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 12/15/2018 |
Start Date: | May 21, 2018 |
End Date: | September 30, 2019 |
Prospective Collection of Whole Blood Specimens From Pregnant Women at Any Risk of Fetal Chromosomal Anomaly for the Development of a Noninvasive Prenatal Test
The purpose of this study is to collect whole blood samples from women with viable
pregnancies of at least 10 weeks gestation (at any risk for fetal chromosomal anomaly) for
future testing with an investigational noninvasive prenatal test(s) (NIPTs), and to establish
clinical truth compared to a clinical reference standard.
pregnancies of at least 10 weeks gestation (at any risk for fetal chromosomal anomaly) for
future testing with an investigational noninvasive prenatal test(s) (NIPTs), and to establish
clinical truth compared to a clinical reference standard.
This is a prospective, multi-center specimen collection study; each subject's treatment,
management, or medical care will not be determined by the study protocol.
Women 18 years of age or older with a viable pregnancy of at least 10 weeks gestation will be
enrolled. A whole blood sample will be collected from each subject.
Subjects will be followed until data or specimens used to establish the clinical reference
standard are collected, and pregnancy outcome and birth information is collected (if
applicable). If cytogenetic test results from standard-of-care procedures are not available
and pregnancies end in live births, a neonatal buccal swab specimen will be collected.
Maternal specimens will be processed to plasma and stored for future testing with an
investigational NIPT(s). There will be no investigational NIPT results nor centralized CMA
LDT results generated under this protocol.
Cytogenetic results from standard-of-care procedures and microarray results will be used to
classify the clinical status of subjects according to the clinical reference standard.
management, or medical care will not be determined by the study protocol.
Women 18 years of age or older with a viable pregnancy of at least 10 weeks gestation will be
enrolled. A whole blood sample will be collected from each subject.
Subjects will be followed until data or specimens used to establish the clinical reference
standard are collected, and pregnancy outcome and birth information is collected (if
applicable). If cytogenetic test results from standard-of-care procedures are not available
and pregnancies end in live births, a neonatal buccal swab specimen will be collected.
Maternal specimens will be processed to plasma and stored for future testing with an
investigational NIPT(s). There will be no investigational NIPT results nor centralized CMA
LDT results generated under this protocol.
Cytogenetic results from standard-of-care procedures and microarray results will be used to
classify the clinical status of subjects according to the clinical reference standard.
Inclusion Criteria:
- Has a viable pregnancy of at least 10 weeks, 0 days gestation at the time of maternal
specimen collection (singleton or multiple pregnancy acceptable),
- Be 18 years of age or older at enrollment, and
- Is willing and able to provide documentation of informed consent.
Exclusion Criteria:
- Has a prior NIPT result from the current pregnancy,
- Had an invasive prenatal diagnostic procedure (eg, CVS, amniocentesis) in the current
pregnancy before maternal specimen collection,
- Has a history of transplant or malignancy,
- Had a transfusion of blood or blood components up to 8 weeks before maternal specimen
collection,
- Had preimplantation genetic screening for the current pregnancy (for in vitro
fertilization patients only), or
- Has already participated in the study (enrolled previously)
We found this trial at
8
sites
Greensboro, North Carolina 27408
Principal Investigator: Avinash Patil, MD
Phone: 336-544-3327
Click here to add this to my saved trials
Hagerstown, Maryland 21740
Principal Investigator: Andrew Oh, MD
Phone: 301-665-9098
Click here to add this to my saved trials
Jackson, Tennessee 38301
Principal Investigator: Lolly Eldridge, MD
Phone: 731-660-8396
Click here to add this to my saved trials
611 North 35th Street
Morehead City, North Carolina 28557
Morehead City, North Carolina 28557
Principal Investigator: Thomas Vradelis, MD
Phone: 252-247-4297
Click here to add this to my saved trials
Norfolk, Virginia 23502
Principal Investigator: Mohamad M Parva, MD
Phone: 757-471-3375
Click here to add this to my saved trials
Phoenix, Arizona 85004
Principal Investigator: Avinash Patil, MD
Phone: 480-456-6000
Click here to add this to my saved trials
3100 Duraleigh Road
Raleigh, North Carolina 27607
Raleigh, North Carolina 27607
Principal Investigator: Robert Littleton, MD
Phone: 919-788-4465
Click here to add this to my saved trials
Winston-Salem, North Carolina 27103
Principal Investigator: Robert Parker, MD
Phone: 336-397-3703
Click here to add this to my saved trials